Regeneron Pharmaceuticals
REGN
1,400 hedge funds and large institutions have $69.8B invested in Regeneron Pharmaceuticals in 2026 Q1 according to their latest regulatory filings, with 136 funds opening new positions, 578 increasing their positions, 462 reducing their positions, and 103 closing their positions.
32% more first-time investments, than exits
New positions opened: 136 | Existing positions closed: 103
25% more repeat investments, than reductions
Existing positions increased: 578 | Existing positions reduced: 462
1% more funds holding
Funds holding: 1,389 → 1,400 (+11)
1% less capital invested
Capital invested by funds: $70.7B → $69.8B (-$904M)
5% less call options, than puts
Call options by funds: $1.04B | Put options by funds: $1.1B
1.52% less ownership
Funds ownership: 88.65% → 87.13% (-1.5%)
11% less funds holding in top 10
Funds holding in top 10: 27 → 24 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$898M |
| 2 |
Two Sigma Investments
New York
|
+$407M |
| 3 |
JP Morgan Chase
New York
|
+$285M |
| 4 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
+$203M |
| 5 |
AQR Capital Management
Greenwich,
Connecticut
|
+$180M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$614M |
| 2 |
Marshall Wace
London,
United Kingdom
|
-$366M |
| 3 |
Holocene Advisors
New York
|
-$356M |
| 4 |
Millennium Management
New York
|
-$243M |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
-$226M |
REGN Hedge Fund Activity: Q1 2026 in Review
1,400 of the 8,208 institutional investors tracked by Wall St. Rank reported a position in Regeneron Pharmaceuticals (REGN) for Q1 2026, worth a combined $69.8B — down 1.3% from $70.7B a quarter earlier.
Buyers outnumbered sellers: 136 funds opened new REGN positions and 103 closed out — a net gain of 33 holders — while 578 added to existing stakes and 462 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $898M. The largest seller was Fidelity Investments, cutting an estimated $614M.
- 1,400 institutional investors held Regeneron Pharmaceuticals (REGN) as of Q1 2026, up from 1,389 in Q4 2025.
- Funds reported $69.8B of Regeneron Pharmaceuticals stock for Q1 2026, down 1.3% quarter-over-quarter.
- 136 funds opened new Regeneron Pharmaceuticals positions in Q1 2026 and 103 closed out, a net change of +33 holders.
- The largest Regeneron Pharmaceuticals buyer in Q1 2026 was Wellington Management Group, an estimated $898M added.
- The largest Regeneron Pharmaceuticals seller in Q1 2026 was Fidelity Investments, an estimated $614M sold.
Based on aggregated 13F filings for Q1 2026.